Share on LinkedInShare on LinkedIn

ARTICLE · 21 JULY 2014

Federal Court Questions Disclosure Requirement In Sound Prediction Cases

Torys
Torys
Contributor
Torys

Torys

Torys LLP is an international business law firm that works with clients who expect the best advice...

View firm profile
Explore more from Torys

On July 2, 2014, the Federal Court released its trial decision on the validity of the patent for esomeprazole, a proton pump inhibitor.

CanadaIntellectual Property

On July 2, 2014, the Federal Court released its trial decision on the validity of the patent for esomeprazole, a proton pump inhibitor (PPI) sold by AstraZeneca as Nexium® for the treatment of gastric-acid-related diseases.1 Esomeprazole is a single enantiomer of omeprazole, which was known to be an effective PPI at the time the patent was filed.2

This case was an impeachment action brought by Apotex, which challenged the esomeprazole patent for lack of utility, anticipation and obviousness. The Court ultimately found the patent to be invalid on the basis of lack of utility. The decision is notable because of the Court's analysis of the law on the disclosure requirement of sound prediction, an issue that has been the subject of substantial discussion in the courts since it was first articulated by the Supreme Court of Canada (SCC) in Apotex v. Wellcome3 and later revisited in Teva v. Pfizer.4

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from